Aura Biosciences

First pharmacological treatment for ocular melanoma

Aura BioSciences is using its proprietary VDC (virus-like particle-drug conjugates) platform to develop products to treat high unmet needs in ocular and urologic cancers.

Aura’s clinical pipeline includes AU-011, its most advanced product, which is poised to begin registrational studies in primary choroidal melanoma and which is also in Phase I studies in non-invasive muscle bladder cancer.

CEO  Elisabet de los Pinos

aurabiosciences.com

Advent Contact  Raj Parekh

Advent invested in the Series B in 2015.
Publicly Listed
29 March 2023 in Aura Biosciences, Press Release, Private Companies, Publicly Listed

Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013

Press Release.   ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB) Additional IND filing for ZKN-013 for treatment of familial adenomatous polyposis…
Read More
16 February 2023 in Aura Biosciences, Press Release, Private Companies, Publicly Listed

Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration

Press Release.   Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal…
Read More
1 December 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Announces Pricing of Public Offering of Common Stock

Press Release. BOSTON--(BUSINESS WIRE)-- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced…
Read More
10 November 2022 in Aura Biosciences, Press Release, Publicly Listed

Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Press Release. Announced the Global Phase 3 Trial Design with Suprachoroidal Route of Administration of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma First Patient Dosed in the Phase 1 Study Evaluating…
Read More